I would say a few on here have read almost all the historical trials and research papers on Bisantrene. Everything points in the right direction. The only thing that is needed is clinical data / validation. P1 will provide this as part of dose escalation. That is why it’s going to be critical either way. If it’s not Cardio protective in P1 it won’t suddenly be protective in P2 or P3.
Good news is Bisantrene cardioprotective in-vitro and in-vivo (mouse model), which has good translation to ppl for cardiac issues.
p.s. Bisantrene is a modified heart friendly version of Doxorubicin.
Cardioprotection thread, page-363
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2826 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.095 ( 6.64 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.41 | $1.32 | 16145 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |